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Abstract 34 
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of 35 
reproductive age. PCOS is associated with multiple co-morbidities including, obesity, insulin 36 
resistance and type 2 diabetes, as well as mood disorders and impaired quality of life (QoL). 37 
Obstructive sleep apnoea (OSA) is also a common medical condition that is often 38 
undiagnosed, particularly in women. OSA is associated with a similar spectrum of 39 
comorbidities to that observed in PCOS, including manifestations of the metabolic syndrome 40 
and impaired QoL, whilst obesity frequently constitutes a common denominator in the 41 
pathophysiology of both OSA and PCOS. Hence, it is not surprising that OSA and PCOS 42 
may co-exist in women of reproductive age, and the current clinical guidelines on the 43 
management of PCOS recommend screening for OSA symptoms in overweight/obese women 44 
with PCOS. In this review, we examine the relationship between OSA and PCOS and explore 45 
the potential underlying mechanisms that link these two conditions.  46 
  47 
Page 3 of 20 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
1. Introduction 48 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of 49 
reproductive age with a prevalence of 6–15% (3, 4). PCOS is associated with obesity, 50 
subfertility, insulin resistance (IR) and type 2 diabetes (T2DM), depression and impaired 51 
quality of life (QoL) (1, 5). However, despite its high prevalence and significant co-52 
morbidities, our understanding of its underlying pathophysiology remains poor; with limited 53 
treatment options available to manage this lifelong disorder in everyday clinical practice. 54 
Hence, there is a need to improve the understanding of the pathogenesis of PCOS and the 55 
spectrum of factors that might contribute to the clinical manifestations and comorbidities of 56 
this very common condition. 57 
Obstructive sleep apnoea (OSA) is also an obesity-related disorder. OSA prevalence in the 58 
general population is estimated at 17–26% in men and 9–28% in women, but this difference 59 
varies depending on the definition and methods used to diagnose OSA (6). OSA is 60 
characterised by recurrent episodes of partial (hypopnoea) or complete (apnoea) upper airway 61 
obstructions associated with recurrent oxygen desaturations and cyclical changes in heart 62 
rate, blood pressure, intrathoracic pressure and sympathetic activity (7). In addition, OSA 63 
results in changes in the sleep architecture, including loss of deep sleep (stages 3 and 4) 64 
and/or of REM sleep (7).  65 
Patients with OSA may present with nocturnal symptoms, including snoring, witnessed 66 
apnoea episodes, choking or gasping, insomnia, nocturia, enuresis, frequent arousals, 67 
diaphoresis, and impotence (8). In addition, common daytime OSA symptoms may include 68 
excessive daytime sleepiness, fatigue, memory impairment, morning headaches, and 69 
depression (8). Prompt diagnosis and treatment of OSA is highly important in clinical 70 
practice, since undiagnosed/untreated OSA is associated with increased risk of hypertension, 71 
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cardiovascular disease, mortality, IR and T2DM, road traffic accidents, depression and 72 
impaired QoL (8, 9) . Continuous positive airway pressure (CPAP) therapy, combined with 73 
weight loss for overweight/obese patients, is the treatment of choice for symptomatic OSA 74 
(10). 75 
Despite the high prevalence of OSA in the general population, this condition is generally 76 
under-recognised and frequently remains undiagnosed in everyday clinical practice, 77 
particularly in women who may not present with typical OSA symptoms (11). As obesity is a 78 
common risk factor, it is not surprising that OSA and PCOS might co-exist. The association 79 
between PCOS and OSA has also been recognised in the latest guidelines by the European 80 
and the US Endocrine Societies (Box 1) (1, 2). However, these guidelines acknowledge the 81 
limited evidence behind their recommendations that is largely based on limited, ‘weak’, or 82 
‘low quality’ data. This highlights the need for further research to better understand the 83 
relationship between PCOS and OSA. In addition, the implications of OSA in women with 84 
PCOS are not clear, though important as both conditions are associated with overlapping 85 
comorbidities, and OSA is associated with essential factors that may contribute to the burden 86 
of PCOS (e.g. to IR, increased inflammation, and oxidative stress) (6, 12). In this article we 87 
present a concise review of key studies that examined the relationship between OSA and 88 
PCOS, and we explore the potential mechanisms linking both conditions. 89 
 90 
Box 1. Clinical guidelines/recommendations on screening women with PCOS for OSA. 
1. Endocrine Society, 2013 (1): 
We suggest screening overweight/obese adolescents and women with PCOS for symptoms 
suggestive of OSA and, when identified, obtaining a definitive diagnosis using 
polysomnography. If OSA is diagnosed, patients should be referred for institution of 
appropriate treatment. 
2. European Society of Endocrinology, 2014 (2): 
It seems wise at this moment to screen sleep disorders by clinical questionnaires in obese 
women with PCOS. In the case of clinical suspicion resulting from these questionnaires, 
patients should be referred to a centre of sleep disorders for polysomnography and further 
evaluation. 
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2. Methodology 91 
We conducted a narrative review of the relevant literature. In this context, we searched 92 
PubMed using the terms ‘(PCOS OR polycystic ovary syndrome) AND (OSA OR obstructive 93 
sleep apnoea OR obstructive sleep apnea)’. Clinical studies and review articles examining the 94 
presence of OSA in women with PCOS were obtained, reviewed, and their results were 95 
critically appraised. We also hand-searched references from relevant papers and review 96 
articles. 97 
3. Epidemiology 98 
3.1 PCOS prevalence in OSA 99 
PCOS has a prevalence of 6–15% in women of reproductive age (3); however, the reported 100 
prevalence rates vary depending on the populations studied and the applied PCOS diagnostic 101 
criteria. The prevalence of PCOS in women with OSA remains unknown. 102 
 103 
3.2 OSA prevalence in PCOS 104 
The prevalence of OSA in the general population varies considerably between studies, mainly 105 
due to differences in the populations studied, study designs, and the methods and criteria used 106 
to diagnose OSA (8). The prevalence from three well-conducted studies with similar designs 107 
from the USA (Wisconsin and Pennsylvania), and Spain showed an OSA prevalence of  9–108 
28% in women, with 2–7% for moderate to severe OSA (13).  109 
To date, a limited number of studies have examined the prevalence of OSA in women with 110 
PCOS with the majority of these being conducted in the USA. Based on the existing 111 
published studies (14-22) (Table 1), the reported prevalence of OSA in women with PCOS 112 
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ranges from 0% to 69% (median: 55.8%; mean: 39.8%). This large variability and wide range 113 
in the reported prevalence may be attributed to a combination of reasons, including 114 
application of different cut-off points and methods to diagnose OSA, the small size of the 115 
studied cohorts, and potential selection bias by recruitment of study participants from 116 
specialised clinics. As expected, the available data suggest that OSA risk in women with 117 
PCOS is increased with age and obesity. While the only published study that examined the 118 
presence OSA in lean women with PCOS showed no evidence of the condition (18), the 119 
small number of study participants (n=18) precludes generalisability or drawing firm 120 
conclusions from these data. The reported prevalence and potential links between PCOS and 121 
OSA in adolescents are even more controversial, with one study showing a prevalence of 122 
16/28 (57%) (20) and another showing 0/22 (0%) prevalence (19). Based on the available 123 
data on the prevalence and natural history of these two conditions, it is probable that PCOS 124 
precedes the development of OSA; however, it cannot be excluded that OSA may precede the 125 
clinical presentation of PCOS in some women, worsening the PCOS-related 126 
symptomatology. Observational long-term studies are needed to accurately assess the 127 
incidence of OSA in women with PCOS and vice versa. 128 
 129 
4. Proposed mechanisms linking OSA to PCOS and its comorbidities 130 
Depending on ethnicity and geography, 30–88% of women with PCOS are overweight or 131 
obese (23). Obesity may contribute to the development of PCOS through increased android 132 
(central) type adiposity and IR (24); lipotoxicity (25); and increased 5α-reductase activity 133 
(23). Obesity is also a major risk factor for OSA (8). The mechanisms that link obesity to 134 
OSA are multifactorial (8, 26). Weight gain can alter normal upper airway mechanics during 135 
sleep by various mechanisms, such as increased parapharyngeal fat deposition resulting in a 136 
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smaller upper airway; altering the neural compensatory mechanisms that maintain airway 137 
patency; reducing the functional residual capacity with a resultant decrease in the stabilising 138 
caudal traction on the upper airway; reducing lung volume due to increased abdominal fat; 139 
increasing breathing workload due to increased chest wall thickness; and affecting the 140 
chemosensitivity to O2 and CO2 which reduces the ventilatory drive (8, 26). Subsequently, 141 
obesity is a key factor that predisposes to both PCOS and OSA. However, other shared 142 
features between PCOS and OSA may also play an important mechanistic role in the 143 
development/interaction between these two common conditions. 144 
4.1 Sex Hormones 145 
An increase in circulating androgens of ovarian origin is one of the main features of PCOS 146 
and is present in both ovulatory and anovulatory women. Androgens cause many of the 147 
clinical features of PCOS (e.g. hirsutism, acne and alopecia); contribute to anovulation by 148 
promoting ovarian early follicular growth and subsequently disrupt follicular development 149 
and dominant follicle selection (27); and exacerbate IR. Anovulation will result in lower 150 
progesterone levels. Hyperandrogensim and low progesterone levels may play a role in the 151 
pathogenesis of OSA by increasing upper airway collapsibility, and/or impairing the 152 
sensitivity and responsiveness of the ventilatory chemoreceptors (28). However, the effect of 153 
hyperandrogenism on OSA risk in women with PCOS is probably small, as androgen levels 154 
are relatively low compared to men. Sleep, on the other hand, appears to have a significant 155 
effect on the female hormone production (29). Indeed, sleep deprivation and/or interruption, 156 
and sleep disordered breathing have been suggested to influence gonadotropin releasing 157 
hormone (GnRH), follicular stimulating hormone (FSH) and luteinising hormone (LH) 158 
pulsatility and may cause menstrual disturbances (30, 31). Subsequently, OSA may alter sex 159 
hormones production and contribute to the development or worsening of the clinical features 160 
of PCOS. 161 
Page 8 of 20Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9 
 
4.2 Insulin resistance 162 
IR is seen in more than 50% of women with PCOS, independent of obesity (32). Insulin may 163 
act directly on the ovaries to enhance androgen production (33); reduce SHBG production 164 
from the liver with subsequent increase in bioavailable testosterone; and cause the premature 165 
arrest of follicle growth and anovulation (34). Most studies also suggest an association 166 
between OSA and IR (8); and studies in healthy lean men found OSA to be associated with 167 
IR even in the absence of obesity (35). In addition, in a cohort study, OSA, apnoea/hypopnea 168 
index (AHI), oxygen desaturation index (ODI), and minimal oxygen saturations were 169 
independently associated with IR development over an 11-year follow-up period after 170 
adjustment for age, baseline BMI, BMI change over follow-up, hypertension, and CPAP 171 
treatment (36). Two recent meta-analyses showed that CPAP treatment was associated with a 172 
reduction in the homeostasis model assessment of insulin resistance (HOMA-IR) (37, 38), 173 
although this benefit may occur only in those using CPAP >4 hours per night (39). 174 
Subsequently, it is plausible that OSA, through IR, may contribute to the development of a 175 
more severe PCOS phenotype in women affected by both conditions; or to a de novo 176 
presentation of PCOS in genetically/metabolically predisposed women. 177 
4.3 Oxidative stress 178 
In a recent systematic review and meta-analysis, PCOS was associated with increased levels 179 
of oxidative stress, independent of age and BMI (40). Oxidative stress may play a role in the 180 
pathogenesis of PCOS by exacerbating IR (41); causing hyperandrogenism (41); and 181 
contributing to infertility (42). Many studies suggest that OSA is a cause of oxidative stress 182 
(8). Recurrent hypoxia and mitochondrial dysfunction in OSA result in the formation of 183 
reactive oxygen species (ROS) which leads to cellular and DNA damage and oxidative stress 184 
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(43). Subsequently, OSA may complicate the clinical picture in PCOS by promoting 185 
oxidative stress.  186 
4.4 Endothelial dysfunction 187 
Women with PCOS have been found to have lower flow-mediated dilatation (FMD) 188 
compared to age- and weight-matched controls (44). Obesity, IR, oxidative stress, advanced 189 
glycation end products (AGE) and inflammation are believed to play a role in the 190 
pathogenesis of endothelial dysfunction in PCOS (45). OSA is also associated with 191 
endothelial dysfunction and the underlying mechanisms are likely related to ischemia-192 
reperfusion injury (46). Repetitive episodes of re-oxygenation after hypoxemia in patients 193 
with OSA result in increased production of AGE and ROS (43); altered protein kinase C 194 
signaling; decreased endothelial nitric oxide synthase (47); increased endothelin-1 levels and 195 
inflammation (48). Notably, CPAP treatment was found to increase FMD in patients with 196 
OSA (49). 197 
4.5 Sympathetic activity 198 
Sympathetic activity is increased in obesity and is associated with visceral adiposity (50); 199 
high leptin levels (51) and IR (52) are thought to play a role in its pathogenesis. However, 200 
increased sympathetic activity may further exacerbate IR and creates a vicious cycle (52). 201 
Women with PCOS have evidence of increased sympathetic activity (52), even in the absence 202 
of obesity (53). Sympathetic activity may contribute to the pathogenesis of PCOS through 203 
increased IR, altered ovarian function and the development PCO morphology (52). OSA is 204 
also associated with an increase in sympathetic activity independent of body weight (54). It is 205 
likely that both the recurrent hypoxia (55) and recurrent arousals (56) contribute to the 206 
activation of the sympathetic nervous system (SNS). Moreover, treatment with CPAP is 207 
associated with a reduction in sympathetic activity (57).  208 
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4.6 Summary of the proposed mechanisms linking OSA and PCOS 209 
OSA and PCOS are both associated with comorbidities including obesity, IR, oxidative 210 
stress, endothelial dysfunction, sympathetic hyperactivity, and hormonal disturbances that 211 
could potentially contribute to the pathophysiology and development of either condition. It is 212 
thus plausible that the relationship between OSA and PCOS is bidirectional, where PCOS 213 
contributes to the development of OSA, and vice versa, OSA contributes to the clinical 214 
presentation of PCOS, worsening its symptomatology and creating a vicious cycle between 215 
the two conditions. An illustration of the possible pathophysiological links between OSA and 216 
PCOS and their clinical consequences is provided in Figure 1. 217 
 218 
 219 
5. The impact of OSA in women with PCOS 220 
5.1 Review of published studies 221 
A limited number of studies have examined the effect(s) of OSA in women with PCOS and 222 
their findings are summarised in Table 1. 223 
In the study by Vgontzas et al. (15), women with PCOS and sleep disordered breathing (SDB 224 
was defined as either OSA or upper airway resistance syndrome; n=9) were heavier (BMI 225 
45.7±2.6 vs. 37.2±1.1 kg/m
2
, P<0.003), and had higher fasting insulin (306.5±52.4 vs. 226 
176.1±18.5 pmol/L, P<0.01) and lower glucose-to-insulin ratio (0.02±0.006 vs. 0.04±0.003, 227 
P<0.05) compared to women with PCOS without SDB (n=44). Logistic regression analysis of 228 
the study data showed that insulin levels and glucose-to-insulin ratio had a stronger 229 
association with SDB than age, BMI, or testosterone levels. However, the difference in BMI 230 
between the two groups in this study was rather high (8.5 kg/m
2
), and despite statistical 231 
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adjustment, it is difficult to completely rule out an effect of obesity on the metabolic 232 
differences between the two groups. 233 
Similarly, in the study by Tasali et al. (17), women with PCOS and OSA (n=29) were older 234 
(age 31.6±1.0 vs. 27.3±0.7 years; P=0.002), had a higher BMI (42.2±1.1 vs. 35.3±1.4 kg/m
2
 ; 235 
P<0.001), and were more insulin resistant (HOMA-IR 5.7±0.4 vs. 3.5±0.4, P=0.006) than 236 
women with PCOS without OSA (n=23). After controlling for age, BMI, and ethnicity, AHI 237 
was a highly significant predictor of the fasting concentrations of glucose and insulin, as well 238 
as of the 2-h glucose concentration (after an oral glucose tolerance test) and HOMA-IR. The 239 
data of this study also suggest that the degree of sleep fragmentation, rather than the severity 240 
of hypoxia, may be related to the severity of IR and glucose intolerance in women with 241 
PCOS. As such, the authors further concluded that women with PCOS and OSA represent a 242 
metabolically different, ‘higher risk’ population compared to women with PCOS without 243 
OSA. However, this conclusion should be taken with caution considering the small study 244 
sample size, and the relatively large difference in BMI (7.1 kg/m
2
) between women with and 245 
without OSA in this study. 246 
Notably, Tasali et al. have also conducted a relevant short-term interventional study (58) in 247 
19 obese women with PCOS and OSA (age ± SEM: 31.2±1.2 years; BMI: 46.4±2.4 kg/m
2
). 248 
These women were treated with CPAP for 8 weeks, exhibiting subsequent improvement in 249 
insulin sensitivity (relative increase of nearly 7%), and reduction in diastolic blood pressure 250 
(DBP; approximately 2.3 mmHg). In addition, day-time and night-time norepinephrine levels 251 
also reduced after CPAP therapy. However, this study lacked a control group, and only a ‘per 252 
protocol’ analysis was performed including just 9 study participants, with the data from 253 
another 10 study patients being excluded from the analysis due to lack of adequate CPAP 254 
treatment compliance (average use of CPAP <4 hours per night). Of note, whether the 255 
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reported post-treatment changes in IR and blood pressure observed in this study may 256 
translate/result into meaningful clinical outcomes remains to be studied.  257 
In another study by Tock et al. (21), women with PCOS and OSA (n=12) had higher BMI 258 
(37.8±4.8 vs. 30.67±7.7 kg/m
2
, P=0.006); waist circumference (114.4±12.0 vs. 98.1±19.9 cm, 259 
P=0.013); waist-to-hip ratio (1.0±0.1 vs. 0.9±0.1, P=0.029); free testosterone (1.9±1.3 vs. 260 
1.1±0.8 ng/dL, P=0.014); HOMA-IR (4.4±3.2 vs. 2.3±1.4, P=0.009); total cholesterol 261 
(205.0±28.7 vs. 172.3±35.8 mg/dL, P=0.009); low density lipoprotein-cholesterol (LDL,  262 
128.6±21.6 vs. 98.9±29.6, P=0.004); and higher prevalence of non-alcoholic fatty liver 263 
disease (NAFLD, 83.3% vs. 26.9%, P<0.001) compared to those without OSA (n=26). After 264 
adjusting for obesity in multivariate logistic regression analysis, raised serum free 265 
testosterone levels ≥1.07 ng/dL increased the risk of OSA in women with PCOS by 8.2 fold. 266 
Accordingly, the authors concluded that hyperandrogenism may be a predisposing factor for 267 
OSA in PCOS. However, a limitation of this study is the fact that testosterone was measured 268 
by immunoassay rather than by tandem mass spectrometry. In a subsequent multiple logistic 269 
regression analysis, with OSA (AHI ≥5), IR (HOMA-IR ≥2.7), and obesity (BMI ≥30 kg/m
2
) 270 
considered as independent variables and NAFLD as the dependent variable, only OSA was an 271 
independent predictor of the presence of NAFLD. The presence of OSA increased the chance 272 
of NAFLD 7.6 fold in woman with PCOS. As such, the authors concluded that OSA is a 273 
predictor of NAFLD along with, but independent of, obesity and IR. 274 
In a recent study by Chatterjee et al. (22), women with PCOS and SDB (n=33) had higher 275 
BMI (29.8±3.4 vs. 24.36±2.29 kg/m
2
, P<0.001), waist circumference (95.58±6.47 vs. 276 
85.12±4.34, P<0.001), systolic BP (SBP, 129.27±10.93 vs. 119.18±8.03 mmHg, P=0.002), 277 
diastolic BP (78.61±9.07 vs. 73.53±6.22 mmHg, P=0.044), and hirsutism (Ferriman–Gallwey 278 
score 9.82±2.78 vs. 8.00±2.5, P=0.028) compared to women with PCOS without SDB 279 
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(n=17). Interestingly, in a logistic regression analysis which adjusted for BMI, only the 280 
associations between fasting plasma glucose and diastolic BP with SDB remained significant.  281 
Finally, in the study by Nandalike et al. (20), adolescent girls with PCOS and OSA (n=16) 282 
had higher prevalence of the metabolic syndrome (56.3% vs. 8.3%, P=0.03); higher HOMA-283 
IR >4 (81.3% vs. 41.6%, P=0.03), systolic BP (128.4±12.8 vs. 115.6±11.4 mmHg, P=0.009), 284 
triglycerides (149.7±87.7 vs. 93.3±25.8 mg/dl, P=0.03), and lower high density lipoprotein 285 
(HDL, 38.6±8.7 vs. 49±10.9 mg/dl, P=0.01) compared to girls with PCOS without OSA 286 
(n=12). 287 
 288 
5.2 Summary of the literature 289 
It seems plausible that OSA is associated with the severity of the PCOS phenotype, 290 
particularly in overweight/obese and insulin resistant women with PCOS. However, it is 291 
difficult to draw firm conclusions from the studies conducted so far since significant 292 
variables (e.g. abdominal adiposity and ethnicity) have often not been accounted for in the 293 
presented analyses. In addition, while the association between OSA and increased insulin 294 
resistance in women with PCOS seems to be a common theme, the relationship between OSA 295 
and hyperandrogenism is more controversial and require further evaluation. While the US 296 
and European Endocrine societies’ guidelines consider the presence of OSA as a 297 
cardiovascular risk factor in women with PCOS (1, 2), there is lack of data on the exact 298 
relationship between OSA and important clinical outcomes in women with PCOS (e.g. on 299 
T2DM risk, cardiovascular risk, subfertility, depression, and impaired QoL). Subsequently, 300 
well conducted observational studies are needed to examine the effects of OSA in women 301 
with PCOS. Interventional studies are also required in women with PCOS and OSA. The 302 
existing short-term, pilot, interventional study in such patients suggests that CPAP therapy 303 
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may significantly improve insulin sensitivity and reduce blood pressure. However, it remains 304 
unclear whether this can translate into long-term meaningful clinical outcomes.  305 
 306 
6. Conclusions 307 
OSA appears to be common in obese women with PCOS. There is a lack of high-quality 308 
evidence regarding the clinical benefit or the cost-effectiveness of the current Endocrine 309 
Society clinical practice guidelines which suggest screening all overweight/obese adolescents 310 
and women with PCOS for symptoms suggestive of OSA. While it is probable that PCOS 311 
precedes and contributes to the development of OSA, it is also plausible that OSA may 312 
contribute to the presentation and worsen the clinical manifestations of PCOS. Both 313 
conditions are associated with significant comorbidities in women (e.g. depression, 314 
unexplained fatigue, hypertension, dyslipidaemia, IR and impaired glucose tolerance), and 315 
may progress undiagnosed for prolonged periods. In order to inform clinical practice and 316 
support evidence-based guidelines, further clinical research is needed, including prospective 317 
cohort studies in obese and non-obese women with PCOS, to study in detail the relationship 318 
between these two important and prevalent conditions.  319 
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Study Notes n OSA Women with PCOS and OSA compared to women with PCOS without OSA 
   Diagnosis % 
Weight 
or BMI 
WC or 
WHR 
IR 
Hyperandro-
genism 
BP FPG IGT MS 
Vgontzas et 
al. 2001; (15) 
USA 53 
AHI ≥10 +  
symptoms 
11–17% ↑ NA Insulin ↑* FT and TT ↔ NA ↔ NA NA 
Fogel et al. 
2001; (14) 
USA 18 AHI >10 66.8% NA ↑ NA NA NA NA NA NA 
Gopal et al. 
2002; (16) 
USA 23 
RDI ≥5 + 
symptoms 
69.6% ↔ NA NA NA NA NA NA NA 
Tasali et al. 
2008; (17) 
USA 52 AHI ≥5 55.8% ↑ NA HOMA-IR ↑* FT and TT ↔ NA ↔ ↑ NA 
Yang et al. 
2009; (18) 
Taiwan,  
lean women 
18 AHI ≥ 5 0%         
De Sousa et 
al. 2010; (19) 
Germany, 
adolescents 
22 Not stated 0%         
Nandalike et 
al. 2012; (20) 
USA, 
adolescents, 
retrospective 
28 
AHI >5 or  
apnoea index >1 
57.2% ↔ NA HOMA-IR ↑ FT and TT ↔ ↑ ↔ NA ↑ 
Tock et al. 
2014; (21) 
Brazil 38 AHI ≥5 31.6% ↑ ↑ HOMA-IR ↑ FT ↑* NA ↔ ↑ NA 
Chatterjee et 
al. 2014; (22) 
India 50 
RDI ≥5 + 
symptoms or 
RDI >15 
66% ↑ ↑ HOMA-IR ↔ FT ↔ ↑ ↑* NA ↑ 
Table 1 Differences between women with PCOS and OSA compared to women with PCOS only. n, number of participants; OSA, obstructive sleep 
apnoea; PCOS, polycystic ovary syndrome; AHI, apnoea/hypopnea index; RDI, respiratory distress index; BMI, body mass index; WC, waist circumference; 
WHR, waist-to-hip-ratio; IR, insulin resistance; HOMA-IR, homeostatic model assessment of insulin resistance; FT, Free testosterone; TT, total testosterone; 
BP, blood pressure; FPG, fasting plasma glucose; IGT, impaired glucose tolerance; MS, metabolic syndrome; ↑ statistically significant increase; NA, not 
available; ↔ equal; *adjusted for weight. 
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Figure 1. Possible mechanisms linking common shared features between Obstructive 
Sleep Apnoea (OSA) and Polycystic Ovary Syndrome (PCOS) with their clinical 
consequences. 
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